A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-018-0387-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Treatment With Tumour Infiltrating Lymphocytes and Interleukin-2 in Patients With Metastatic Melanoma: A Pilot Study

Biotherapy
1992English

A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
1996English

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients With Primary Melanoma

PLoS ONE
Multidisciplinary
2014English

Dose Efficacy Study of Two Schedules of High-Dose Bolus Administration of Interleukin 2 and Interferon Alpha in Metastatic Melanoma

British Journal of Cancer
Cancer ResearchOncology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy